Paweł H.
- Country
- Poland
- Department
- PL10007: Rheumatology
Research Overview
- Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 339 of 573 partner sites.
Specializations
Rheumatoid arthritis
Clinical research activity includes rheumatoid arthritis and ACPA-positive rheumatoid arthritis, with interest in patients who have persistent inflammatory disease despite background methotrexate treatment.
- Moderate-to-severe rheumatoid arthritis
- ACPA-positive rheumatoid arthritis
- ACR20 and DAS28-ESR response assessment
- TNFR1 pathway targeting
- Biologic and biosimilar therapies
The therapeutic focus extends to biosimilar evaluation and immune-mediated joint disease control in adults with active disease.
Psoriatic arthritis
There is strong involvement in psoriatic arthritis, particularly active disease requiring advanced immunomodulatory therapy to reduce joint inflammation and symptom burden.
- Active psoriatic arthritis
- ACR50 and ACR20 response endpoints
- IL-17 and IL-23 pathway therapies
- JAK inhibition
- Long-term safety and tolerability
Research activity also includes treatment options for patients with prior inadequate response to established biologic DMARDs.
Systemic lupus erythematosus and cutaneous lupus erythematosus
Clinical trial work is centered on systemic lupus erythematosus and cutaneous lupus erythematosus, with attention to both global disease activity and skin-specific manifestations.
- Moderate-to-severe systemic lupus erythematosus
- Cutaneous lupus erythematosus
- BICLA, SRI-4, and CLASI-A outcomes
- Type I interferon and TNF-related mechanisms
- Background standard-of-care lupus therapy
The portfolio includes therapies aimed at systemic control, mucocutaneous disease, and persistent inflammatory activity in adult patients.
Sjögren’s disease
Another major area of interest is Sjögren’s disease, including patients with moderate-to-severe systemic involvement and those with significant symptom burden.
- Primary Sjögren’s disease
- Systemic disease activity
- ESSDAI and clinESSDAI assessment
- B-cell directed therapies
- Patient-reported symptom control
The therapeutic scope emphasizes control of glandular and extraglandular manifestations in autoimmune disease.
Myositis and other systemic autoimmune diseases
Additional research activity covers dermatomyositis, myositis, and broader systemic autoimmune disease populations, reflecting interest in multi-organ inflammatory disorders.
- Dermatomyositis
- Systemic manifestations
- Immune-mediated muscle and skin disease
- Long-term safety evaluation
- Novel immunotherapy development
This area also includes investigation of therapies for overlapping autoimmune phenotypes with musculoskeletal and cutaneous involvement.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.